Vagal Nerve Stimulation‐Modulation of the Anti‐Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis
Key result
Transcutaneous vagus nerve stimulation modulated the immune response and reduced disease activity and CRP-levels in patients with psoriatic arthritis and ankylosing spondylitis.
Why the study?
Does noninvasive transcutaneous vagus nerve stimulation improve clinical disease activity and systemic inflammation in patients with psoriatic arthritis or ankylosing spondylitis?
Population
40 patients in remission, comprising 20 with psoriatic arthritis and 20 with ankylosing spondylitis.
Design
Cohort, open-label
Follow-up
5 days
Authors
Discussion
Loading...
Member takes
Implication
tVNS was associated with reduced PsA activity and CRP; leaves open neuromodulation benefit in spondyloarthritis pending RCTs.
Structured PICO
Does noninvasive transcutaneous vagus nerve stimulation improve clinical disease activity and systemic inflammation in patients with psoriatic arthritis or ankylosing spondylitis?
P
Population
40 patients with psoriatic arthritis or ankylosing spondylitis in remission treated with transcutaneous vagus nerve stimulation for 5 days.
I
Intervention
Noninvasive transcutaneous vagus nerve stimulation (bilateral, handheld stimulator for 120 seconds 3 times a day for 5 consecutive days).
O
Outcome
Clinical disease activity and systemic levels of inflammation (cardiac vagal tone, clinical scores, CRP, and cytokine levels).surrogate
Transcutaneous vagus nerve stimulation may offer a safe, non-pharmacological add-on therapy to reduce inflammation and disease activity in patients with psoriatic arthritis and ankylosing spondylitis.
Limitations
- open-label design
Cite This Study
Brock et al. (2021) studied psoriatic arthritis or ankylosing spondylitis (n=40). transcutaneous vagus nerve stimulation was evaluated on clinical disease activity and systemic levels of inflammation. Transcutaneous vagus nerve stimulation modulated the immune response and reduced disease activity and CRP-levels in patients with psoriatic arthritis and ankylosing spondylitis.